Join to view full profile
17 E 102nd StNew York, NY 10029
Phone+1 212-241-8100
Fax+1 646-537-8921
Dr. Grinspan is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Ari Grinspan, MD, is a gastroenterologist based in New York, NY, who completed his medical education at Albert Einstein College of Medicine in 2008, followed by a residency in internal medicine at New York Presbyterian Hospital (Cornell Campus) and a fellowship in gastroenterology at Icahn School of Medicine at Mount Sinai. He has expertise in general gastroenterology, inflammatory bowel disease, and colorectal cancer. His published research focuses on microbiome therapeutics and fecal microbiota transplantation, with articles featured in reputable journals such as Nature Microbiology and Gastroenterology. Additionally, he has played a key role in clinical trials regarding fecal microbiota transplantation for ulcerative colitis.
Education & Training
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalFellowship, Gastroenterology, 2011 - 2014
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2008 - 2011
Albert Einstein College of MedicineClass of 2008
Certifications & Licensure
NY State Medical License 2011 - 2028
NJ State Medical License 2022 - 2027
American Board of Internal Medicine Gastroenterology
Clinical Trials
- Refined Fecal Microbiota Transplantation (FMT) for Ulcerative Colitis (UC) Start of enrollment: 2021 Nov 10
Roles: Sponsor-Investigator, Contact, Principal Investigator
Publications & Presentations
PubMed
- Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection.Salam P Bachour, Ari Grinspan
Gastroenterology Clinics of North America. 2026-09-01 - 15-strain live biotherapeutic product or same donor fecal microbiota transplant for recurrent Clostridioides difficile infection: a randomized phase 1b trial.Lukas Bethlehem, Lorenza Bartu, Gina Marke, Phyu Mar, Sari Feldman
Nature Medicine. 2026-07-01 - A Randomized, Placebo-Controlled Trial Evaluating Multi-Species Synbiotic Supplementation for Bloating, Gas, and Abdominal Discomfort.Jessica R Allegretti, Zain Kassam, Colleen R Kelly, Ari Grinspan, Najwa El-Nachef
Nutrients. 2026-01-14
Press Mentions
Microbes Behind Successful Fecal Microbiota Transplantations May Become Basis for New TreatmentsSeptember 28th, 2021- Potential Alterative to FMT in Bacteria May Restore Gut MicrobiomeSeptember 27th, 2021
- What Are GI's Biggest Disrupters?September 13th, 2021
Grant Support
- Comparison of defined live biotherapeutic product and fecal microbiota transplantation for treatment of recurrent Clostridioides difficile infectionICAHN SCHOOL OF MEDICINE AT MOUNT SINAI2022–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
